U.S. company licenses rights to long-acting testosterone preparation

August 4, 2005

Indevus Pharmaceuticals, Inc., Lexington, MA has licensed exclusive U.S. rights from Schering AG, Germany to market Nebido, a long-acting injectable testosterone preparation for the treatment of male hypogonadism.

Indevus Pharmaceuticals, Inc., Lexington, MA has licensed exclusive U.S. rights from Schering AG, Germany to market Nebido, a long-acting injectable testosterone preparation for the treatment of male hypogonadism. Nebido, which was recently approved and launched in Europe, requires dosing only once every 3 months.

Under the agreement, Indevus will be responsible for the development and commercialization of the drug in the United States. Schering will be responsible for manufacturing and supplying commercial product to Indevus.

Indevus said it currently anticipates filing a new drug application with the FDA in the second half of 2006.